Improving Immunotherapy Through Glycodesign.
Front Immunol
; 9: 2485, 2018.
Article
en En
| MEDLINE
| ID: mdl-30450094
ABSTRACT
Immunotherapy is revolutionizing health care, with the majority of high impact "drugs" approved in the past decade falling into this category of therapy. Despite considerable success, glycosylation-a key design parameter that ensures safety, optimizes biological response, and influences the pharmacokinetic properties of an immunotherapeutic-has slowed the development of this class of drugs in the past and remains challenging at present. This article describes how optimizing glycosylation through a variety of glycoengineering strategies provides enticing opportunities to not only avoid past pitfalls, but also to substantially improve immunotherapies including antibodies and recombinant proteins, and cell-based therapies. We cover design principles important for early stage pre-clinical development and also discuss how various glycoengineering strategies can augment the biomanufacturing process to ensure the overall effectiveness of immunotherapeutics.
Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Productos Biológicos
/
Ingeniería Biomédica
/
Proteínas Recombinantes
/
Inmunoterapia
/
Anticuerpos
Idioma:
En
Revista:
Front Immunol
Año:
2018
Tipo del documento:
Article